Crossmark

Effects of Omegaven®, EPA, DHA and oxaliplatin on oesophageal adenocarcinoma cell lines growth, cytokine and cell signal biomarkers expression

Crossref DOI link: https://doi.org/10.1186/s12944-018-0664-1

Published Online: 2018-01-30

Published Print: 2018-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Eltweri, Amar M.

Howells, Lynne M.

Thomas, Anne L.

Dennison, Ashley R.

Bowrey, David J.
More Information

Article History

Received: 20 October 2017

Accepted: 17 January 2018

First Online: 30 January 2018

Ethics approval and consent to participate

: Not applicable

: Not applicable

: A M Eltweri, A R Dennison and D J Bowrey received departmental grant support from Fresenius Kabi for clinical trial investigating the effects of Omegaven® intravenous supplement in patients with advanced oesophagogastric adenocarcinoma receiving palliative chemotherapy. A R Dennison have received speaking honoraria from Fresenius Kabi. D J Bowrey has received departmental grant support for unrelated work from Nutricia. The other authors have no conflicts to declare.

: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.